Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RBL1 Monoclonal Antibody (OTI4E1)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA527449
Description
RBL1 Monoclonal Antibody for Western Blot
RB-like 1 is similar in sequence and possibly function to the product of the retinoblastoma 1 (RB1) gene. The RB1 gene product is a tumor suppressor protein that appears to be involved in cell cycle regulation, as it is phosphorylated in the S to M phase transition and is dephosphorylated in the G1 phase of the cell cycle. Both the RB1 protein and RB-like 1 can form a complex with adenovirus E1A protein and SV40 large T-antigen, with the SV40 large T-antigen binding only to the unphosphorylated form of each protein. In addition, both proteins can inhibit the transcription of cell cycle genes containing E2F binding sites in their promoters. Due to the sequence and biochemical similarities with the RB1 protein, it is thought that RB-like 1 may also be a tumor suppressor.
Specifications
RBL1 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3 | |
P28749 | |
RBL1 | |
Human recombinant protein fragment corresponding to amino acids 739-1014 of RBL1 produced in E.coli. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Western Blot | |
OTI4E1 | |
Unconjugated | |
RBL1 | |
107 kDa retinoblastoma-associated protein; AW547426; CP107; DNA-binding protein RFX5; MGC40006; p107; pRb1; RB transcriptional corepressor like 1; Rbl1; Regulatory factor X 5; regulatory factor X, 5 (influences HLA class II expression); regulatory factor X5; retinoblastoma-like 1; retinoblastoma-like 1 (p107); retinoblastoma-like protein 1; RFX5 | |
Mouse | |
Affinity chromatography | |
RUO | |
5933 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction